Control of Sinus Node Tachycardia as an Additional Therapy in Patients

Status Recruiting

Clinical Trial Summary

Study aims to compare the I(f) inhibitor ivabradine with placebo as strategy of heart rate control in patients with decompensated heart failure (DHF).

Clinical Trial Description

Sympathetic hyperactivity and consequent increase in heart rate (HR) are physiological responses to low cardiac output in patients with decompensated heart failure (DHF). However, elevated HR may become inappropriate in these patients, increasing myocardial oxygen demand and decreasing diastolic filling time and might lead to hemodynamic deterioration, ventricular dysfunction (tachycardiomyopathy) and clinical deterioration.

Studies show the elevated HR is a predictor of poor prognosis in DHF. Subanalyses of large clinical trials using beta blockers (BBs) demonstrate the adequate control of HR correlates with a better outcome in patients with stable chronic heart failure (HF). However, use of BBs in patients with DHF is limited due to negative inotropic and hypotensive effects of these drugs.

As alternative to BBs, ivabradine has shown to increase survival of patients with chronic stable systolic HF. Compared to BBs, ivabradine has the advantage of "pure" negative chronotropic effect, no effect on myocardial contractility or peripheral vascular resistance. Despite the inhibition of I (f) has been validated as a therapeutic option in patients with stable HF, there are no studies available on this strategy in patients with DHF.

We hypothesized that HR control by ivabradine might improve clinical, hemodynamic and neurohormonal parameters in patients with DHF. The aim of this study was to evaluate the efficacy of HR control with ivabradine in patients with DHF. ;

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02236247
Study type	Interventional
Source	University of Sao Paulo
Contact	Marco S. Alves, MD
Phone	+55 11 981431512
Email	marco.alves@incor.usp.br
Status	Recruiting
Phase	Phase 1/Phase 2
Start date	May 2013
Completion date	August 2017

View Details

See also
Status	Clinical Trial	Phase
Not yet recruiting	`NCT05910437` - Optimizing Treatments for Heart Failure During Hospitalization
Terminated	`NCT00355017` - BNP Guided Care in Addition to Multidisciplinary Care	N/A
Active, not recruiting	`NCT03701880` - Early Use of Ivabradine in Heart Failure	N/A
Recruiting	`NCT03157219` - Manipal Heart Failure Registry (MHFR)	N/A
Recruiting	`NCT06114498` - Hospital Register of Decompensated Heart Failure With Preserved Ejection Fraction
Completed	`NCT03838003` - Exercise in Patients Admitted With Recently Decompensated Heart Failure	N/A
Recruiting	`NCT02997462` - Monocyte Phenotypic Changes in Heart Failure
Completed	`NCT04493346` - Shear Wave Elastography
Recruiting	`NCT02666651` - Regional Tolvaptan Registry	Phase 4
Not yet recruiting	`NCT06273397` - Acetazolamide or Metolazone in Acute Heart Failure	N/A
Recruiting	`NCT06286423` - Colchicine in Acutely Decompensated HFREF	Phase 4
Completed	`NCT05927285` - Effect on Kidney Function Recovery Guiding Decongestion With VExUS in Patients With Cardiorenal Syndrome 1	N/A
Withdrawn	`NCT04572867` - Aquapheresis Efficacy in Outpatients With Decompensated Heart Failure	N/A
Completed	`NCT02157506` - A Dose Ranging Phase IIa Study of 6 Hour Intravenous Dosages of CXL-1427 in Patients Hospitalized With Heart Failure	Phase 2
Recruiting	`NCT03914222` - Comparing PA Compliance During and After Decompensation in HFP	N/A
Recruiting	`NCT03009552` - Speckle Tracking Echocardiography Adds Information in Decompensated Heart Failure	N/A
Completed	`NCT04019314` - Assessment of ProEnkephalin to Detect Acute Kidney Injury (AKI)	N/A
Recruiting	`NCT02649517` - Clinical and Morphological Characteristics of Chronic Inflammation in the Myocardium in Patients With Decompensated HF With Ischemic Systolic Dysfunction	N/A
Recruiting	`NCT03440970` - Mechanism and Effects of Manipulating Chloride Homeostasis in Stable Heart Failure	Early Phase 1
Recruiting	`NCT05090930` - Innovative Technologies for the Treatment of Pulmonary and Heart Failure	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Control of Sinus Node Tachycardia as an Additional Therapy in Patients With Decompensated Heart Failure — CONSTATHE

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms